Zebrafish heterotrimer G-protein gamma 2 subunit (GNG2)
First Claim
Patent Images
1. An isolated expression vector comprising a polynucleotide consisting of:
- (a) SEQ ID NO;
1 and (b) a sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO;
2.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides sequences of the zebrafish heterotrimeric G-protein gamma 2 subunit (GNG2). The invention also provides methods of inhibiting and promoting GNG2-dependent angiogenesis in vertebrates, particular mammals, including humans, for the treatment of angiogenesis-related diseases. The invention also provides methods of identifying compounds that promote or inhibit angiogenesis through their interaction with GNG2. The invention further provides methods of modulating angiogenesis through the modulation of both GNG2 and VEGF.
-
Citations
38 Claims
-
1. An isolated expression vector comprising a polynucleotide consisting of:
-
(a) SEQ ID NO;
1 and(b) a sequence encoding a polypeptide having the amino acid sequence of SEQ ID NO;
2. - View Dependent Claims (2, 6)
-
-
3. An antibody that specifically binds to a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2 with high affinity, but which does not bind a polypeptide comprising the amino acid sequence of SEQ ID NO;
4 or SEQ ID NO;
5 with high affinity. - View Dependent Claims (4, 5, 9)
- 2 with high affinity, but which does not bind a polypeptide comprising the amino acid sequence of SEQ ID NO;
- 7. A therapeutic composition comprising, an isolated polynucleotide comprising a nucleic acid sequence encoding zebrafish GNG2 and a pharmaceutically acceptable carrier.
-
10. A therapeutic composition comprising a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2 and a pharmaceutically acceptable carrier.
- 11. A method of treating an angiogenesis-related disease comprising administering to a patient in need of such treatment a polynucleotide of that inhibits the expression of GNG2 in an amount sufficient to inhibit angiogenesis.
- 15. A method of promoting angiogenesis in an animal in need thereof, comprising administering to an animal an effective amount of a polynucleotide encoding a GNG2 polypeptide.
- 18. A method of treating an angiogenesis-related disease comprising administering to a patient in need of such treatment a first polynucleotide that inhibits the expression of GNG2 and a second polynucleotide that inhibits the expression of VEGF, wherein said first polynucleotide and said second polynucleotide are provided in an sufficient to inhibit angiogenesis.
- 22. A method of treating a patient with an angiogenesis-dependent tumor comprising administering to a patient in need of such treatment a first compound that inhibits the expression or function of GNG2 and a second compound that inhibits the expression or function of VEGF, wherein said first compound and said second compound are provided in amount sufficient to cause tumor regression.
- 23. A method of promoting angiogenesis in an animal in need thereof comprising administering to an animal an effective amount of a first polynucleotide encoding a GNG2 polypeptide and an effective amount of a second polynucleotide encoding a VEGF polypeptide.
- 28. A method of treating an angiogenesis-related disease comprising administering to a patient in need of such treatment a first compound that inhibits the function of GNG2 and a second compound that inhibits the function of VEGF, wherein said first compound and said second compound are provided in an sufficient to inhibit angiogenesis.
- 30. A method for identifying a compound that inhibits GNG2 activity comprising contacting a test compound with a GNG2 polypeptide and determining whether said test compound inhibits the activity of GNG2, wherein a test compound that inhibits the activity of GNG2 is identified as an antagonist of GNG2.
- 37. A method of inhibiting angiogenesis comprising administering to a cell an effective amount of a cell permeable peptide that inhibits the biological function of GNG2.
Specification